Rumor Has It: Can Biogen Find A Buyer For Hemophilia Drugs?
This article was originally published in Scrip
Executive Summary
It's no secret that Biogen Inc. has been facing some issues over the last year as shares have dropped, management has exited and the company has made staffing cuts, but the latest rumors have the big biotech selling off one of its lucrative franchises. The move would not only be a drastic shift for the company, but begs the question: who would buy?
You may also be interested in...
Biogen Backs Out Of Hemophilia, But Who Benefits?
With no buyers in the hemophilia space and a need to create a more streamlined company, Biogen Inc. announced May 3 that it has done the only thing it can – spin out its hemophilia business. It's still unclear whether this will be a positive strategy for either company.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.